Actively Recruiting
Phase I Study Evaluating Capivasertib Pharmacokinetics and Safety in Adults With Moderate Hepatic Impairment Compared to Normal Liver Function
Led by AstraZeneca · Updated on 2026-09-09
20
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the pharmacokinetics, safety, and tolerability of capivasertib in adults with moderate hepatic impairment compared to those with normal liver function. This Phase I, single-dose, non-randomized, open-label study aims to understand how the drug behaves in the body under these conditions and to monitor its safety. The study includes participants aged 18 to 80 years and is sponsored by AstraZeneca. Participants will be divided into two groups those with moderate hepatic impairment and those with normal liver function. Each participant will receive a single oral dose of capivasertib while residing at the study site from the day before dosing through four days after. Participants with hepatic impairment will have an additional liver function stability assessment during screening. After dosing, participants will return for a follow-up visit 9 to 11 days later. During the study, participants will undergo blood sampling to measure capivasertib concentrations and various pharmacokinetic parameters such as maximum plasma concentration and area under the curve from day 1 to day 4. Researchers will also monitor adverse events up to day 11 to assess safety. The total participation lasts from screening through follow-up visits, with close monitoring during residence at the study site.
CONDITIONS
Brief Title
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here